AbbVie Inc.
corporate_fare Company Profile
AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek monitors ABBV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- AbbVie's $11B Apogee Deal, EU Nod for Boey, and Sellas Bid Interest Fuel Rally
- EU Approves AbbVie's Fast-Acting Frown Line Treatment Boey
- AbbVie Lowers Full-Year EPS Guidance by $0.17 Due to Q2 IPR&D Expenses
- AbbVie's TEPKINLY Approved in Europe for Follicular Lymphoma, Offering Chemotherapy-Free Option
- AbbVie's Epcoritamab Achieves Phase 3 Win in DLBCL Trial
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ABBV, detected from its recent SEC filings · based on capital-structure filings through 2026-02-26.
Finalized $8.0 Billion Debt Offering · Use of Proceeds
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →